Insight Research
Quatre Bornes, Mauritius, 72218
NCT Number: NCT07194408
Atopic dermatitis is a chronic skin condition requiring sun protection, yet research on sunscreen effectiveness and skin tolerance in Atopic Dermatitis is limited. This study evaluates a broad-spectrum SPF50+ sunscreen on 22 children with Atopic Dermatitis, assessing skin tolerance through dermatologic and pediatric controls.
Looking for future studies?
Notify Me3 year–11 year
All sexes
Observational
Quatre Bornes, Mauritius, 72218
Atopic dermatitis is a chronic skin condition that necessitates sun protection, yet there is limited research on the effectiveness of sunscreens and skin tolerance in Atopic Dermatitis.
Objectives: This study aims to evaluate the tolerance of a broad-spectrum SPF50+ sunscreen in children with Atopic Dermatitis, monitored through dermatological and pediatric assessments.
Methods: This study is conducted on 22 children with Atopic Dermatitis confirmed using the SCORAD index (15-25).
The protocol includes 2 visits and assessments as follow:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Criteria related to the population:
Criteria Related to Atopic Dermatitis:
Non-Inclusion Criteria:
Criteria Related to Population:
Criteria Related to Subject's Health:
Dermo-cosmetic product, Broadspectrum Sunscreen RV4620A RP2552, very high protection product.
Instructions for product use given to the subjects: Apply before and during sun exposure, at least twice daily. During sun exposure, applications must be renewed as often as necessary, in particular after swimming, perspiring, towelling, in order to ensure a good protection. On days of bad weather, apply the product in the morning and at the beginning of the afternoon.
Time frame: At the end of the study, after Last Patient Out, (after Day 22)
Global tolerance is assessed on the "tolerance population" which includes all the subjects who applied at least once investigational product.
This assessment allows for attribution of one of the 5 levels : excellent, very good, good, moderate, bad.
Time frame: Visit 3 (Day 22)
The subjects' parent(s)/ legal representatives give their global appreciation about the product with positive and negative feedback. According to the items, the subjects' parent(s)/ legal representatives have to answer opened questions and a question using a scale from 0 to 10.
Pierre Fabre Dermo Cosmetique
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07653386
Atopic Dermatitis (AD), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hanoi, Vietnam
View Trial DetailsNCT05959083
Atopic Dermatitis (AD), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Beijing, Beijing Municipality, China
View Trial DetailsNCT07329101
Atopic Dermatitis (AD), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hangzhou, Zhejiang, China
View Trial DetailsNCT06810050
Atopic Dermatitis (AD), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Fremont, California, United States
View Trial Details